Original research article| Volume 75, ISSUE 1, P40-44, January 2007

Weekly contraception with mifepristone



      The study investigated the contraceptive effect of weekly administration of mifepristone.

      Subjects and Methods

      A double-blind, randomized clinical trial with weekly doses of 25 or 50 mg of mifepristone was carried out in three centers in China. Women were assigned to either of two groups. We defined each study cycle as 28 days. All bleeding data were derived from women's menstrual cards. The outcome measures were contraceptive efficacy, changes of menstrual pattern and side effects.


      Eighty-three women were enrolled and the outcome was known in 76 women: 39 in the 25-mg group and 37 in the 50-mg group. No pregnancy occurred in both groups in 456 women-months of use accumulated. There were no significant differences in mean bleeding days and no bleeding days between the two groups in the first three study cycles. In the fourth, fifth and sixth cycles, mean bleeding days in the 50-mg group (0.86, 1.05 and 0.62, respectively) were significantly less than those in the 25-mg group (3.5, 2.87 and 2.4 respectively); mean no bleeding days in the 50-mg group (26.07, 25.95 and 26.11, respectively) were significantly more than those in the 25-mg group (22.93, 23.23 and 23.51, respectively), and the percentage of women who had no bleeding in a 28-day study cycle in the 50-mg group (22.3%, 25% and 21.1%, respectively) was significantly more than those in the 25-mg group (2.6%, 3.9% and 3.9%, respectively). Side effects, such as nausea and breast distension, were uncommon and mild.


      Once weekly administration with 25-mg mifepristone is a potentially effective method for regular contraception.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Marions L.
        • Danielsson K.G.
        • Swahn M.L.
        • et al.
        Contraceptive efficacy of low doses of mifepristone.
        Fertil Steril. 1998; 70: 813-816
        • Cheng J.
        • Weng L.
        • Han X.
        • Xiao B.
        Study on weekly low doses of mifepristone for contraception.
        Zhonghua Fu Chan Ke Za Zhi. 2001; 36 ([Chinese]): 424-427
        • Godfrey E.M.
        • Mawson J.T.
        • Stanwood N.L.
        • Fielding S.L.
        • Schaff E.A.
        Low-dose mifepristone for contraception: a weekly versus planned postcoital randomized pilot study.
        Contraception. 2004; 70: 41-46
        • Chen X.
        • Xiao B.
        Effect of once weekly administration of mifepristone on ovarian function in normal women.
        Contraception. 1997; 56: 175-180
        • Spitz I.M.
        • Croxatto H.B.
        • Salvatierra A.M.
        • Heikinheimo O.
        Response to intermittent RU486 in women.
        Fertil Steril. 1993; 59: 971-975
        • Danforth D.R.
        • Williams R.F.
        • Hsiu J.G.
        • et al.
        Intermittent GnRH antagonist plus progestin contraception conserving tonic ovarian estrogen secretion and reducing progestin exposure.
        Contraception. 1990; 41: 623-631
        • Singh M.M.
        Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders.
        Med Res Rev. 2001; 21: 302-347
        • Lal J.
        • Nitynand S.
        • Asthana O.P.
        • Nagaraja N.V.
        • Gupta R.C.
        Optimization of contraceptive dosage regimen of Centchroman.
        Contraception. 2001; 63: 47-51
        • Potter L.
        • Oakley D.
        • de Leon-Wong E.
        • Canamar R.
        Measuring compliance among oral contraceptive users.
        Fam Plann Perspect. 1996; 28: 154-158
        • David S.S.
        • Huggins G.R.
        • Garcia C.R.
        • Busacca C.
        A synthetic steroid (R2323) as a once-a-week oral contraceptive.
        Fertil Steril. 1979; 31: 278-281
        • Bartl R.
        • Gotte S.
        • Hadji P.
        • Hammerschmidt T.
        Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment.
        Dtsch Med Wochenschr. 2006; 131: 1257-1262
        • Recker R.R.
        • Gallagher R.
        • MacCosbe P.E.
        Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women.
        Mayo Clin Proc. 2005; 80: 856-861